(Source: September 2007; Stemedica Cell Technologies, Inc.)
Stemedica Cell Technologies announced at a media conference September 13th that it has established a partnership with Hospital Angeles-Tijuana, part of Grupo Angeles Servicios de Salud, the largest private hospital group in Mexico. Hospital Angeles will provide adult stem cell treatments under strict clinical study protocol to patients afflicted with specific medical conditions associated with Alzheimer’s, Parkinson’s, Multiple Sclerosis, Muscular Dystrophy, Stroke, Ischemic Brain Trauma, Spinal Cord Injury and other neurodegenerative conditions and diseases.
At the conference, Maynard Howe, Ph.D, CEO and Vice-Chairman of Stemedica, explained that Stemedica was formed when a relative was seriously injured in a car accident. The family began to explore various treatments for spinal cord injuries and discovered that Russia had been developing stem cell technology for over 30 years. The relative, who was a quadriplegic, has undergone two treatments in Russia. Since then, she has regained the use of her upper body and is now learning to walk again, as she demonstrated for the audience at the media conference.
According to Dr. Howe, the partnership with Hospital Angeles – Tijuana is an exciting opportunity to work with the leading hospital chain in Mexico. “Hospital Angeles is a state of the art facility providing the highest level of care.”
At the conference, Dr. Cesar Amescua, the hospital’s medical director, gave an in-depth presentation regarding patient treatments using adult stem cells. Dr. Amescua said “We expect to demonstrate the safety and efficacy of adult stem cell treatments in patients through use of Stemedica’s innovative technology. We will advance these treatments following a strict Clinical Study Protocol as approved by our Ethics and Internal Review Board Committees.”
Stemedica is in the process of interviewing a number of highly-accredited treatment facilities that may eventually become Clinical Research Centers where adult stem cell therapy using Stemedica International product can take place under regulatory-approved Clinical Study Protocols.